[go: up one dir, main page]

MX2021003730A - Agentes y métodos para modular la actividad patógena. - Google Patents

Agentes y métodos para modular la actividad patógena.

Info

Publication number
MX2021003730A
MX2021003730A MX2021003730A MX2021003730A MX2021003730A MX 2021003730 A MX2021003730 A MX 2021003730A MX 2021003730 A MX2021003730 A MX 2021003730A MX 2021003730 A MX2021003730 A MX 2021003730A MX 2021003730 A MX2021003730 A MX 2021003730A
Authority
MX
Mexico
Prior art keywords
methods
agents
pathogen activity
receptor
complement
Prior art date
Application number
MX2021003730A
Other languages
English (en)
Inventor
Michael P Jennings
Jennifer L Edwards
Christopher J Day
Johnson Mak
Original Assignee
Univ Griffith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Griffith filed Critical Univ Griffith
Publication of MX2021003730A publication Critical patent/MX2021003730A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción se refiere al uso de ligandos del receptor 3 del complemento, incluyendo ligandos del dominio I de la subunidad alfa de este receptor, en métodos, composiciones y artículos/dispositivos para inhibir la interacción de patógenos con una célula que expresa el receptor 3 del complemento y para tratar o inhibir el desarrollo de infecciones causadas por dichos patógenos.
MX2021003730A 2018-09-28 2019-09-30 Agentes y métodos para modular la actividad patógena. MX2021003730A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862739025P 2018-09-28 2018-09-28
PCT/AU2019/051055 WO2020061649A1 (en) 2018-09-28 2019-09-30 Agents and methods for modulating pathogen activity

Publications (1)

Publication Number Publication Date
MX2021003730A true MX2021003730A (es) 2021-06-18

Family

ID=69949189

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003730A MX2021003730A (es) 2018-09-28 2019-09-30 Agentes y métodos para modular la actividad patógena.

Country Status (11)

Country Link
US (1) US20210338685A1 (es)
EP (2) EP4295864A3 (es)
KR (1) KR102824220B1 (es)
CN (2) CN118986994A (es)
AU (1) AU2019348194B2 (es)
BR (1) BR112021005955A2 (es)
CA (2) CA3115048C (es)
DK (1) DK3856196T3 (es)
MX (1) MX2021003730A (es)
SG (1) SG11202103183PA (es)
WO (1) WO2020061649A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111184707B (zh) * 2020-02-20 2021-04-27 中山大学 托芬那酸或其药学上可接受的盐在制备预防和/或治疗新型冠状病毒炎症药物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) 1960-08-09 New n-heterocyclic compounds
US2554736A (en) 1951-05-29 Tertiary aminoalkyl-iminodibenzyls
US2868818A (en) 1953-12-15 1959-01-13 Merck & Co Inc Alpha methyl phenylalanines
US3515785A (en) 1958-12-06 1970-06-02 Geigy Chem Corp Compositions and methods for treating endogenous depression with 3-chloro - 5 - (gamma - dimethylamino - propyl)-iminodibenzyl
DE1142870B (de) 1959-11-16 1963-01-31 Geigy Ag J R Verfahren zur Herstellung von Azepinderivaten
US3138636A (en) 1960-06-23 1964-06-23 Parke Davis & Co Anthranilic acid derivatives
US3462536A (en) 1960-07-22 1969-08-19 Merck & Co Inc Method of inhibiting decarboxylase
US3454554A (en) 1960-10-14 1969-07-08 Colgate Palmolive Co Aminoalkyliminodibenzyl compounds
US3313848A (en) 1964-06-18 1967-04-11 Parke Davis & Co Anthranilic acids and derivatives
FR1532301A (fr) 1967-01-18 1968-07-12 Rhone Poulenc Sa Nouveaux dérivés de la dibenzazépine et leur préparation
CH500196A (de) 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US4092430A (en) 1970-09-09 1978-05-30 Ciba-Geigy Corporation Antiphlogistic phenylacetohydroxamic acid compositions
US4692441A (en) * 1985-08-16 1987-09-08 Merck & Co., Inc. Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
DE3811119C1 (es) 1988-03-31 1989-10-12 Merckle Gmbh, 7902 Blaubeuren, De
IT1226902B (it) 1988-07-12 1991-02-21 Mini Ricerca Scient Tecnolog Processo per la sintesi del levodopa
PT101732B (pt) 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
WO1997016181A1 (en) * 1995-11-03 1997-05-09 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
IN190806B (es) 1998-11-16 2003-08-23 Max India Ltd
DE19924148A1 (de) * 1999-05-26 2000-12-07 Univ Heidelberg Sphingomyelinasehemmer
US7261901B2 (en) * 2001-01-31 2007-08-28 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US7250172B2 (en) * 2001-01-31 2007-07-31 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
CA2437402A1 (en) 2001-02-12 2002-08-22 Teva Pharmaceutical Industries, Ltd. New crystal forms of oxcarbazepine and processes for their preparation
WO2006116157A2 (en) * 2005-04-22 2006-11-02 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-iv inhibitors
WO2008139484A2 (en) 2007-05-16 2008-11-20 R. L. Fine Chem New process for the synthesis of loferpramine maleate: a stable salt of loferpramine
KR101141938B1 (ko) * 2010-01-22 2012-05-04 성균관대학교산학협력단 신규한 항생제 조성물 및 그람양성균의 치료 방법
TWI619494B (zh) * 2013-01-18 2018-04-01 華鴻新藥股份有限公司 巴豆酯之組成物及使用方法
JP6713003B2 (ja) 2015-01-26 2020-06-24 インスティテュート フォー クリニカル ファーマコダイナミクス， インコーポレイテッド 感染症を患う被験体における抗感染症療法の期間を短縮する方法
WO2017058735A1 (en) * 2015-09-28 2017-04-06 Research Institute At Nationwide Children's Hospital Compositions and methods for inhibiting the growth of neisseria gonorrhoeae
CN105949075B (zh) 2016-06-24 2017-11-07 江苏倍合德化工有限公司 一种甲芬那酸的合成方法
CN108309983B (zh) * 2018-01-15 2019-11-15 武汉百药联科科技有限公司 卡马西平在制备治疗黄病毒属病毒感染的药物中的应用
US11013707B2 (en) * 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN108324716A (zh) * 2018-04-18 2018-07-27 日照市普达医药科技有限公司 一种含有茚地那韦的抗hiv药物及制备方法

Also Published As

Publication number Publication date
CA3115048A1 (en) 2020-04-02
KR102824220B1 (ko) 2025-06-23
KR20210069086A (ko) 2021-06-10
EP4295864A3 (en) 2024-03-13
AU2019348194B2 (en) 2025-04-03
EP3856196B1 (en) 2023-11-15
SG11202103183PA (en) 2021-04-29
CN113164494A (zh) 2021-07-23
WO2020061649A1 (en) 2020-04-02
CN113164494B (zh) 2024-08-27
CN118986994A (zh) 2024-11-22
EP3856196A1 (en) 2021-08-04
CA3224977A1 (en) 2020-04-02
EP4295864A2 (en) 2023-12-27
DK3856196T3 (da) 2024-02-19
BR112021005955A2 (pt) 2021-07-27
AU2019348194A1 (en) 2021-04-29
CA3115048C (en) 2024-02-13
EP3856196A4 (en) 2022-08-10
US20210338685A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
DOP2018000182A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
CL2016000837A1 (es) “formas isoméricas especificas del 7-hidroxi-6,8-dioxo-n-(2,4,6-triflúorobencil)-1,2,3,4,6,8,12,12a-octahidro-1,4-metanodipirido[1,2-a:1’,2’-d]pirazina-9-carboxamida; composición farmacéutica que los comprende; y su uso en el tratamiento de una infección por vih”.
CL2016002414A1 (es) Compuestos derivados de nucleosidos, inhibidores de la transcriptasa inversas composición farmacéutica que los comprende y su uso en el tratamiento de una infección por vih. pct
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
CL2017001137A1 (es) Recipiente
AR108054A1 (es) Apósitos modificados para heridas
CL2016001364A1 (es) Moduladores de ror gamma (rory)
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
MX380866B (es) Composiciones y métodos para modular la expresión del factor b del complemento.
NI201900096A (es) Moduladores de la expresión de pcsk9
ECSP21026021A (es) Moduladores de la expresión de pnpla3
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
CO2020016675A2 (es) Tiofenocarboxamidas sustituidas y análogos como agentes antibacterianos
UY36332A (es) Composiciones de bacillus pumilus rt1279 y metodos de uso para benefficiar el crecimiento de las plantas
CR20180328A (es) Compuestos de isoindol
MX377168B (es) Sistemas generadores de impulso electrico que utilizan acoplamiento capacitivo.
AR110257A1 (es) Copolímeros y el uso de los mismos en composiciones detergentes
MX2016014245A (es) Composiciones para el cuidado de telas que comprenden polimeros de poliuretano, poliurea y/o poliuretanourea.
CL2016003023A1 (es) “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct
AR103756A1 (es) Jarabes de alulosa
CL2021001246A1 (es) Moduladores de expresión irf5.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
MX2021003730A (es) Agentes y métodos para modular la actividad patógena.
CL2015003752A1 (es) Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico